Mike Brooks
Director
Mike Brooks is a Director at PMCF Investment Banking and serves on the Healthcare & MedTech team. He has more than a decade of professional experience advising public and private companies on buy-side and sell-side M&A mandates, recapitalizations, debt and equity financings, transaction planning assessments and strategic consulting. He has extensive experience across healthcare, business services and industrials sectors.
Prior to joining PMCF, Mike worked as an analyst at a boutique investment bank, focusing on providing financial and strategic analysis, valuation, industry research, due diligence, and preparation of comprehensive client marketing materials. A native of Chicago, Mike earned a BBA in Finance from the University of Iowa. He is a licensed securities representative holding his Series 79 and 63 registrations.
Transaction Experience
PMCF Advises Niowave on its Non-Dilutive Financing from Novartis
PMCF Advises CLM Enterprises, Inc. on its Sale to an Employee Stock Ownership Plan
PMCF Advises Airsupply Jeyco in its Sale to Tide Rock
PMCF Advises Raland Compliance Partners in its Sale to Akkodis, A Global Digital Engineering Company and Part of The Adecco Group
PMCF Advises EZ Concrete Supply in its Sale to Aramsco, an Odyssey Portfolio Company
PMCF Advises Century in its Sale Transaction to Hillcrest Investment Partners
PMCF Advises Marcus Thomas in a Recapitalization Transaction with Svoboda Capital Partners
PMCF Advises Master Automatic in its Majority Sale Transaction to MacLean-Fogg Component Solutions
Publications
MedTech M&A Rebounds in Q2 2026
MedTech M&A activity rebounded in the second quarter of 2026, with 113 announced transactions, up 36% from the first quarter. Strategic acquirers accounted for approximately 60% of transactions as buyers pursued businesses that complement their capabilities and growth priorities. PMCF Investment Banking Director Mike Brooks spoke with Modern Healthcare about the recovery and how greater…
Medical Technology M&A Pulse – Q2 2026
Deal volume increased to 113 transactions in Q2 2026 from 83 in Q1, a 36% sequential gain that marked the busiest quarter since the first quarter of 2025.
Medical Device M&A Remains Active as Buyers Prioritize Quality Over Volume
While MedTech M&A activity has slowed from prior peaks, buyers remain active for the right opportunities.
Medical Technology M&A Pulse – Q1 2026
M&A activity slowed in Q1 2026, with deal volume hitting a multi‑year low, reflecting a shift toward fewer, higher‑conviction transactions.
Medical Technology M&A Pulse – Q4 2025
M&A activity in the Medical Technology sector stayed on par with the previous two quarters, with 105 announced transactions. Volume is significantly lower than the same quarter last year, with 135 deals in Q4 2024.